Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-03-24 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily discusses Novartis' commitment to provide relief aid to Japan earthquake victims, including financial assistance and donations of medicines. There is no detailed financial data, quarterly or annual financial results, or management discussion of financial performance. The document is a regulatory announcement providing information on humanitarian aid and company actions rather than a financial report or earnings release. Given the nature of the Form 6-K and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-03-24 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the completion of an acquisition of a majority stake in Zhejiang Tianyuan, a Chinese vaccines company. It includes details about the acquisition, strategic intentions, and forward-looking statements. There are no financial statements or detailed financial performance data included. The document is an announcement of a corporate transaction (acquisition) rather than a full merger filing or tender offer document. It does not fit the full merger and acquisition filings category (MA) which typically include detailed merger communications or tender offer forms. Instead, it is best classified as a Capital/Financing Update (CAP) because it reports on a significant financing and ownership change event (acquisition of a majority stake). The document length is sufficient and contains substantive information about the transaction, not just a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2011-03-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing clinical trial results for a drug (INC424) and related forward-looking statements. There are no financial statements, detailed financial analysis, or comprehensive management discussion of financial results. The document is a regulatory filing providing material information to investors but does not constitute an annual report, interim report, earnings release, or other detailed financial report. It is not a certification or attestation letter either. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-03-15 English
SC 13D/A
Major Shareholding Notification
2011-03-15 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing an FDA advisory committee recommendation for approval of a drug (QAB149) for COPD. It contains no financial statements or detailed financial analysis, but rather a regulatory update and corporate news. The document length is about 12,756 characters, which is relatively short and focused on a specific announcement rather than a comprehensive report. There is no indication that this is an annual or interim financial report, audit report, earnings release, or other detailed financial filing. It is a regulatory filing providing material information to investors and the SEC about a significant corporate event (FDA advisory committee recommendation). Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-03-10 English
SC TO-T/A Filing
M&A Activity Classification · 100% confidence The document is titled 'Amendment No. 4 to Tender Offer Statement on Schedule TO' filed with the SEC. It relates to a tender offer by Novartis AG and its subsidiaries to purchase shares of Genoptix, Inc. The text discusses the offer price, number of shares tendered, acceptance of shares, and plans to consummate a merger following the tender offer. It also mentions that after the merger, the shares will no longer be listed on NASDAQ. The Schedule TO is a specific SEC filing used for tender offers, which are part of merger and acquisition activities. The document is an amendment to the Schedule TO, indicating it is related to M&A activity rather than a full merger proxy statement or other filings. Therefore, the appropriate classification is 'TAR' for M&A Activity, as it is an announcement and document related to a takeover bid and tender offer.
2011-03-07 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.